Individual Difference in the Pharmacokinetics of a Drug, Pravastatin, in Healthy Subjects

Journal of Clinical Pharmacology

Volumn 43, Issue 11, 2003, Pages 1268-1273

  Ogawa, Katsutoshi ^a,b   Hasegawa, Setsuo ^a   Udaka, Yuko ^b   Nara, Keinosuke ^b   Iwai, Shinichi ^b   Oguchi, Katsuji ^b  

^a Sekino Hospital   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Healthy subjects; Individual difference; Pharmacokinetics; Pravastatin

Indexed keywords

PRAVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; EVALUATION; HUMAN; HUMAN EXPERIMENT; MALE; METABOLIC CLEARANCE RATE; NORMAL HUMAN; PHYSIOLOGY;

ADULT; AREA UNDER CURVE; HUMANS; MALE; METABOLIC CLEARANCE RATE; PRAVASTATIN;

EID: 0142040180     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003257232     Document Type: Article

References (15)

1. Gabrielsson J, Weiner D: Pharmacokinetic and Pharmacodynamic Data Analysis. Stockholm: Swedish Pharmaceutical Press, 1994.
2. Shinjo A: A Guide to Basic Statistics by PC SAS. Tokyo: Tokai University Press, 1995 (in Japanese).
3. Pan HY, DeVault AR, Wang-Iverson D, Ivashkive E, Swanson BN, Sugerman AA: Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 1990;30:1128-1135.
4. Pan HY, Triscari J, DeVault AR, Smith SA, Wang-Iverson D, Swanson BN, et al: Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin. Br J Clin Pharmacol 1991;31:665-670.
5. Singhvi SM, Pan HY, Morrison RA, Willard DA: Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 1990;29:239-243.
6. Botti RE, Triscari J, Pan HY, Zayat J: Concentration of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol 1991;14:256-261.
7. Pan HY, Waclawski AP, Funke PT, Whigan D: Pharmacokinetics of pravastatin in elderly versus young men and women. Ann Pharmacother 1993;27:1029-1033.
8. Pan HY, DeVault AR, Brescia D, Willard DA, McGovern ME, Whigan DB, et al: Effect of food on pravastatin pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther Toxicol 1993;31:291-294.
9. Triscari J, Swanson BN, Willard DA, Cohen AI, Devault A, Pan HY: Steady state serum concentration of pravastatin and digoxin when given in combination. Br J Clin Pharmacol 1993;36:263-265.
10. Sasahara K, Kawabata K, Nakaya N, Gotou Y. Phase 1 study of CS-514, an inhibitor of HMG-CoA reductase 2: pharmacokinetics of CS-514 in healthy volunteers. Rinsho Iyaku 1988;4:45-65 (in Japanese).
11. Tomomi H: Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet 2000;6:397-412.
12. Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH: Biotransformation of pravastatin sodium in human. Drug Metab Dispos 1991;19:740-748.
13. Yamazaki M, Akiyama S, Nishigaki R, Sugiyama Y: Uptake is the rate limiting step in the overall hepatic elimination of pravastatin at steady-state in rats. Pharm Res 1996;13:1559-1564.
14. Niinuma K, Kato Y, Suzuki H, Tyson CA, Weizer V, Dabbs JE, et al: Primary active transport of organic anions on bile canalicular membrane in humans. Am J Physiol 1999;276:1153-1164.
15. SANKYO Co., Ltd.: Instruction to the Medicinal Usage of Pravastatin. Tokyo: SANKYO, 2001 (in Japanese).